---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-048183"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T12:03:30.759197+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics Q1 2025: VCN-01 Ph2b meets endpoints; cash runway extended into Q1 2026

## Summary
- VCN-01 plus gemcitabine/nab-paclitaxel increased OS, PFS, DOR in mPDAC vs SoC alone in Phase 2b.
- Two doses of VCN-01 showed greater OS benefit than one dose in patients receiving ≥4 chemo cycles.
- Closed public offering of 6,818,180 shares and warrants at $1.10/unit, gross proceeds ~$7.5M.
- Cash balance post-offering $14.1M, extending runway into Q1 2026.
- Q1 2025 G&A $1.4M (-25% YoY); R&D $3.0M (-14% YoY).

## SEC filing metadata
- accession: 0001104659-25-048183
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925048183/0001104659-25-048183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925048183/tm2514864d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-048183
- JSON: https://secwatch.observer/filing/0001104659-25-048183.json
- Plain text: https://secwatch.observer/filing/0001104659-25-048183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.